LambdaTest Announces Seamless Azure DevOps Integration for Effortless Test Management
29.7.2025 17:30:00 CEST | Business Wire | Press Release
LambdaTest, a GenAI-powered quality engineering platform, is excited to announce the launch of its Azure DevOps App, designed to streamline test management within the Azure DevOps environment. The LambdaTest Azure DevOps App integrates directly with Azure DevOps through the Azure DevOps Marketplace, providing users with a powerful tool to manage and track their executions. They can also link test cases, track executions of those test cases, and create new test cases with AI or manually in a seamless manner, boosting workflow efficiency and fostering better collaboration across development teams.
The LambdaTest AI Test Manager, which is available through the Azure DevOps Marketplace, enhances the Azure DevOps interface by bringing test management functionalities right where teams are already working. This direct integration allows developers and testers to efficiently handle test cases, whether creating, linking, or tracking them, without switching between different tools or environments.
LambdaTest’s Azure DevOps App offers effortless setup via the Azure DevOps Marketplace with simple authentication. It enables seamless linking of test cases to work items for clear traceability. Users can leverage AI to create contextual test cases by entering requirements or uploading files directly within Azure DevOps. The app provides detailed execution history for visibility into test results and supports easy sharing and review of test cases, enhancing collaboration. This integration streamlines workflows and strengthens coordination between development and testing teams.
"We believe that this integration will significantly enhance the development workflow for our users," said Mayank Bhola, Co-Founder & Head of Products of LambdaTest. "By bringing together test management and Azure DevOps in one platform, teams can now test more efficiently and deliver high-quality products faster. This is yet another step in our mission to streamline the testing process and support seamless CI/CD pipelines across organizations."
LambdaTest’s integration with Azure DevOps is a game changer for organizations looking to enhance their testing workflow. By reducing friction between development and testing, this integration allows teams to accelerate releases while maintaining high-quality standards.
The LambdaTest Azure DevOps App is available now in the Azure DevOps Marketplace, providing teams with an intuitive, all-in-one solution for managing tests within their existing DevOps workflow.
For more information on LambdaTest Azure DevOps App, please visit https://www.lambdatest.com/blog/ai-test-manager-azure-devops-extension/
About LambdaTest
LambdaTest is a GenAI-powered Quality Engineering Platform that empowers teams to test intelligently, smarter, and ship faster. Built for scale, it offers a full-stack testing cloud with 10K+ real devices and 3,000+ browsers.
With AI-native test management, MCP servers, and agent-based automation, LambdaTest supports Selenium, Appium, Playwright, and all major frameworks. AI Agents like HyperExecute and KaneAI bring the power of AI and cloud into your software testing workflow, enabling seamless automation testing with 120+ integrations.
LambdaTest Agents accelerate your testing throughout the entire SDLC, from test planning and authoring to automation, infrastructure, execution, RCA, and reporting.
For more information, please visit https://lambdatest.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250729099836/en/
Contacts
press@lambdatest.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom